GlassScriptPhysician profile
Ahmed Sadek
NPI 1316334048
$2,404.10
in general payments reported to CMS, 2019-2025
10 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.57 · 2022: $122 · 2023: $390 · 2024: $929 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222 · Education: $43.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.62 |
| Education | $43.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $788.16 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $425.57 | 2022-2025 | Remodulin, Tyvaso, Orenitram |
| Cagent Vascular INC | $287.00 | 2025 | Serrantor |
| Boston Scientific Corporation | $276.47 | 2023-2025 | Watchman Flx, Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $256.50 | 2024-2025 | Winrevair |
| Abbott Laboratories | $182.28 | 2024 | Proclaim |
| Paratek Pharmaceuticals, INC. | $109.32 | 2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $39.33 | 2025 | |
| Pfizer INC. | $22.90 | 2025 | |
| Allergan, INC. | $16.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Sadek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.